Treatment bevacizumab which is also known as Avastin is believed not to be effective in treating nonsmall cell lung cancer (NSCLC) in its advanced stage. It has further been reported that patients above the age of 65 are not at all benefited by the treatment as it doesn’t help in improving the life expectancy.
As scientific evidence to prove the effectiveness of bevacizumab is lacking, the medical practitioners have recommended that patients in the advanced stage of NSCLC should not be prescribed with the therapy.
For long, it was believed that the Avastin is capable of improving the quality of life. However, it is for the very first time when doubts over the effectiveness of the drug have been raised. Although it has been recommended that patients with advanced stage of NSCLC should not prescribed with Avastin, patients with ovarian and colon cancer are still being prescribed with the treatment.
It is hoped that the findings would help in finding effective treatment for advanced stage of cancer. The drug Avastin is quite costlier and therefore, it is advisable that patients should not waste their money over a treatment which doesn’t have any scientific evidence to prove the effectiveness of the drug or treatment.
Good News USA
- Verizon announces new AllSet prepaid plans with rollover feature
- AT&T selects two trial locations to transition landline customers away from copper wire line
- Vodafone Foundation launches Instant Network Mini ‘mobile network in a backpack’
- Brunswick and South Morang phone and Internet users being urged to switch to NBN
- BT gets CAT to review its 2012 decision on BSkyB’s sports pricing policy